30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

Amit Sharma; Ingo G H Schmidt-Wolf

doi:10.1186/s13046-021-02184-2

30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective

J Exp Clin Cancer Res. 2021 Dec 9;40(1):388. doi: 10.1186/s13046-021-02184-2.

Authors

Amit Sharma^{1

2}, Ingo G H Schmidt-Wolf³

Affiliations

¹ Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, 53127, Bonn, Germany.
² Department of Neurosurgery, University Hospital Bonn, 53127, Bonn, Germany.
³ Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, 53127, Bonn, Germany. Ingo.Schmidt-Wolf@ukbonn.de.

Abstract

Emerging evidence from the numerous clinical trials involving cytokine-induced killer (CIK) cell therapy suggests that its optimization in combination with other contemporary cancer therapies in a complementary manner (rather than as competition) will be a key to combat cancer.

Keywords: Cytokine-induced killer (CIK) cell therapy; Immunotherapies.

Publication types

Editorial

MeSH terms

Cell- and Tissue-Based Therapy / methods*
Cytokine-Induced Killer Cells / metabolism*
Humans
Immunotherapy / methods*
Neoplasms / drug therapy*
Time Factors